Pulmonary Fibrosi: Novel Therapeutic Development
DOD PR191000Aug 15, 2020 - Oct 30, 2024
Role: PI |
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY
NIH/NIDDK R44DK122903-BMar 2, 2020 - Feb 28, 2021
Role: Co-PI |
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY
NIH/NHLBI R44HL147724-BMar 2, 2020 - Feb 28, 2021
Role: Co-PI |
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY
NIH/NHLBI R44HL147724Aug 1, 2019 - Jan 31, 2020
Role: PI |
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY
NIH/NIDDK R44DK122903Aug 1, 2019 - Jan 30, 2020
Role: Principal Investigator |
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
NIH/NHLBI R41HL127919Apr 25, 2015 - Mar 31, 2016
Role: Principal Investigator |
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS
NIH/NHLBI R41HL122022Sep 1, 2014 - Aug 31, 2015
Role: Principal Investigator |
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS
NIH/NIDDK R41DK100189Sep 5, 2013 - Aug 31, 2014
Role: Principal Investigator |
Liver Inflammation and Injury: Molecular Mechanisms
VA I01BX000525Oct 1, 2010 - Sep 30, 2014
Role: Principal Investigator |
C/EBP beta Peptides for the Treatment of Hepatic Fibrosis
NIH/NIDDK RC1DK087031Sep 30, 2009 - Aug 31, 2012
Role: Co-Principal Investigator |
C/EBP beta SIGNALS HEPATOCYTE PROLIFERATION AND SURVIVAL
NIH/NIDDK R37DK046971Jul 15, 1993 - May 31, 2013
Role: Principal Investigator |
C/EBP BETA IN HEPATOCYTE GENE EXPRESSION &PROLIFERATION
NIH R01DK046971Jul 15, 1993 - Aug 31, 2003
Role: Principal Investigator |
Hepatic Fibrosis: Molecular Mechanisms
NIH/NIDDK R01DK038652Jul 1, 1987 - May 31, 2011
Role: Principal Investigator |